Another study conducted for 6 months in non-metastatic, recurrent PCa post-radical prostatectomy or radiation therapy by Saxe et al. [36] that revealed absolute reduction in PSA in four participants and increased PSAdt in nine of ten total evaluable participants from a median of 11.9 (range, 5.4–50.5) months to 112.3 (range, doubling time 8.9-halving time 10.7) months. The gene discussed is KLK3; the disease is posterior cortical atrophy.